[CRO concept concept continues to rise, Yiqiao China's 20cm daily limit] On September 22, CRO concept concept continued to rise during the session, and Yiqiao China's 20cm daily limit was reported. Previously, Nanhua Biotech had four consecutive boards, Novozymes, and Yiyi Pharmaceuticals rose by more than 10%. Baihua Pharmaceuticals, Yao Shi Technology, Beida Pharmaceuticals, Wanbang Pharmaceuticals, and Nearshore Protein quickly followed suit. On the news, Caitong Securities Research reported that domestic pharmaceutical companies’ overseas licensing transactions for new drugs have driven the gradual recovery of investment and financing, and the demand for biotech research and development has rebounded. The AI ​​pharmaceutical transmission chain has entered a forward cycle, and the model of iteration from accelerated design to wet experiment verification and back-infusion AI model has been initially established, taking the lead in benefiting upstream protein synthesis, pre-clinical CRO and other links.